Yahoo
NYSE - Delayed Quote USD

Becton, Dickinson and Company (BDX)

198.34 +3.18 (+1.63%)
At close: 4:00:03 PM EDT
198.34 0.00 (0.00%)
After hours: 4:08:26 PM EDT
Trade BDX on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Thomas E. Polen Jr.
President, CEO & Chairman 3.59M -- 1973
Mr. Michael C. Feld
Executive VP & Chief Revenue Officer 1.91M -- 1981
Mr. Vitor Roque
Executive VP & CFO -- -- 1983
Ms. Elizabeth McCombs
Executive VP & CTO -- -- 1977
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.
Senior VP & Chief Scientific Officer -- -- --
Mr. Arthur Hu
Executive VP and Chief Information & Digital Officer -- -- --
Mr. Shawn C. Bevec
Senior Vice President of Investor Relations -- -- --
Ms. Lanesha T. Minnix J.D.
Executive VP & General Counsel -- -- 1975
Carla Burigatto
Senior VP & Chief Communications Officer -- -- --
Ms. Meera Gopalakrishnan
Senior VP & Global Chief Marketing Officer -- -- --

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417-1880
United States
201 847 6800 https://www.bd.com
Sector: 
Healthcare
Full Time Employees: 
72,000

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Corporate Governance

Becton, Dickinson and Company’s ISS Governance QualityScore as of October 1, 2026 is 2. The pillar scores are Audit: 3; Board: 6; Shareholder Rights: 1; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 5, 2026 at 12:30 PM UTC

Becton, Dickinson and Company Earnings Date

Recent Events

September 30, 2026 at 12:00 AM UTC

Dividend Date

September 9, 2026 at 12:00 AM UTC

Ex-Dividend Date

August 6, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 22, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 29, 2026 at 12:00 AM UTC

11-K: Annual report of employee stock purchase

May 29, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 22, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 20, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 7, 2026 at 12:00 AM UTC

S-8: Offering Registrations

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: